Showing results for #DepressionTreatment

In a groundbreaking development for maternal mental health, the FDA has approved Brexanolone (Zulresso), the first medication specifically designed to treat postpartum depression (PPD). This approval marks a significant advancement in addressing a condition that affects many new mothers, providing a new avenue of hope and recovery.

Ketamine is revolutionizing mental health treatment with its rapid-acting effects, especially for depression, PTSD, and suicidal ideation. Administered under medical supervision, it offers quick relief for treatment-resistant conditions, though ongoing research is crucial to understand long-term safety and improve accessibility.